Display options
Cite
Garbin F, Eckert K, Buttner P, et al. The influence of the thymic preparation thymex-L on deficient antitumor-activity of monocytes from melanoma patients in-vitro. Oncol Rep. 1995;2(3):469-72doi: 10.3892/or.2.3.469.
Garbin, F., Eckert, K., Buttner, P., Garbe, C., Czarnecki, J., & Maurer, H. (1995). The influence of the thymic preparation thymex-L on deficient antitumor-activity of monocytes from melanoma patients in-vitro. Oncology reports, 2(3), 469-72. https://doi.org/10.3892/or.2.3.469
Garbin, F, et al. "The influence of the thymic preparation thymex-L on deficient antitumor-activity of monocytes from melanoma patients in-vitro." Oncology reports vol. 2,3 (1995): 469-72. doi: https://doi.org/10.3892/or.2.3.469
Garbin F, Eckert K, Buttner P, Garbe C, Czarnecki J, Maurer H. The influence of the thymic preparation thymex-L on deficient antitumor-activity of monocytes from melanoma patients in-vitro. Oncol Rep. 1995 May;2(3):469-72. doi: 10.3892/or.2.3.469. PMID: 21597761.
Copy Download .nbib Format: NLM
Share it on

Oncol Rep. 1995 May;2(3):469-72. doi: 10.3892/or.2.3.469.

The influence of the thymic preparation thymex-L on deficient antitumor-activity of monocytes from melanoma patients in-vitro.

Oncology reports

F Garbin, K Eckert, P Buttner, C Garbe, J Czarnecki, H Maurer

Affiliations

  1. FREE UNIV BERLIN,INST PHARM,D-12169 BERLIN,GERMANY. FREE UNIV BERLIN,UNIV KLINIKUM BENJAMIN FRANKLIN,INST MED STAT & INFORMAT VERARBEITUNG,W-1000 BERLIN,GERMANY. FREE UNIV BERLIN,UNIV KLINIKUM BENJAMIN FRANKLIN,DERMATOL ABT,W-1000 BERLIN,GERMANY. INST IMMUNOL & THYMUS RES,BAD HARZBURG,GERMANY.

PMID: 21597761 DOI: 10.3892/or.2.3.469

Abstract

Recently we demonstrated that, in vitro, prothymosin alpha 1 (ProT alpha), a polypeptide from calf thymus, was able to enhance the deranged tumoristatic activity of peripheral blood monocytes from melanoma patients. Now we report, that the thymic preparation Thymex-L significantly enhanced the level of depressed monocyte activity from 19% to 26%, whereas in normal donor groups no significant change of basal activity (35%) was seen. Although the improvement of median levels of killer cell activity was found to be independent from the disease stage, the Thymex-L effect was only statistically significant in stage I and melanoma patients after chemotherapy. In contrast to ProT alpha, Thymex-L did not further enhance monocyte-mediated cytotoxicity when it was applied in combination with rIFN-gamma. However, after stimulation with rIFN-gamma, the median level of TNF-alpha secretion by melanoma monocytes significantly increased (about 2-fold) when preincubated with Thymex-L. These results indicate that depressed monocyte functions in selected melanoma patients may be partially improved by Thymex-L.

Publication Types